,Canonical_Smiles,drug_name,drug_type,Label
0,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Brinzolamide,-,negative
1,N=C(N)NC[C@H]1COc2ccccc2O1,Guanoxan,2D6-Substrate,negative
2,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O,Bendroflumethiazide,Methyltransferase-Inhibitor,negative
3,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,Vinorelbine,2D6-Substrate,negative
4,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,perhexiline,2D6-Substrate,negative
5,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfafurazole,-,negative
6,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,Ivabradine,3A4-Substrate,negative
7,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
8,CN(C)CCO,Deanol,Methyltransferase-Substrate,negative
9,CCC(C(=O)c1ccc(C)cc1)N1CCCC1,MPBP,2D6-Substrate,negative
10,CN1C2CC[C@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2,tropisetron,2D6-Substrate,negative
11,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,Dexfenfluramine,2E1-Inhibitor,negative
12,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
13,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
14,CCCCCCCCCCCC(=O)O,lauric_acid,2E1-Substrate,negative
15,CNC[C@H](O)c1cccc(O)c1,Phenylephrine,19A-Inducer,negative
16,CNC[C@@H](O)c1ccc(O)cc1,Oxedrine,N_acetyltransferase-Inhibitor,negative
17,NCCc1ccc(O)c(O)c1,Dopamine,19A-Inhibitor,negative
18,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)/C=C\CO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,lilopristone,3A4-Substrate,negative
19,CN1C(=O)C[C@@](C)(c2ccccc2)C1=O,Mesuximide,2C19-Inhibitor,negative
20,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
21,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,2E1-Substrate,negative
22,CN(C)CCOC(c1ccccc1)c1ccccc1,Diphenhydramin,2D6-Substrate,negative
23,Cc1ncsc1CCCl,Clomethiazole,2E1-Inhibitor,negative
24,C[C@@H](Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1,Benfluorex,UGT-Inducer,negative
25,COc1ccccc1OC[C@H]1CNC(=O)O1,Mephenoxalone,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
26,CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,Clotiapine,P450_HFLA-Substrate,negative
27,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,Phenoxybenzamine,3A4-Substrate,negative
28,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],Sodium Edetate,3A4-Substrate,negative
29,COc1cc(N[C@H](C)CCCN)c2ncccc2c1,Primaquine,GST-Inhibitor,negative
30,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Betamethason,19A-Inducer,negative
31,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
32,NC(N)=Nc1nc(CSCCN=CNS(=O)(=O)c2ccc(Br)cc2)cs1,Ebrotidine,-,negative
33,Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Dicloxacillin,Multidrug_resistance_protein_1-Substrate,negative
34,C=CC1CC=CCC1,4_vinylcyclohexene,2E1-Substrate,negative
35,CC(C)(C)C(O)C=Cc1ccc2c(c1)OCO2,Stiripentol,-,negative
36,CCCCNCc1cc(=O)oc2cc(OC)ccc12,BMAMC,2D6-Substrate,negative
37,COc1ccc(C(C)C)cc1CNC1C2CCN(CC2)C1C(c1ccccc1)c1ccccc1,Ezlopitant,2D6-Substrate,negative
38,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,Diltiazem,P450_HFLA-Substrate,negative
39,CCn1ncnc1COc1nn2c(-c3ccccc3F)nnc2cc1C(C)(C)C,TPA_023,3A4-Substrate,negative
40,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Ecabapide,-,negative
41,CC(C)NC[C@@H](O)COc1cccc2ccccc12,Propranolol,P450_HFLA-Substrate,negative
42,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
43,CN(C)C=O,DMF,2E1-Substrate,negative
44,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,Atorvastatin,UGT-Substrate,positive
45,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,Milnacipran,-,negative
46,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
47,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](CC)C[C@@]21C,org_4060,3A4-Substrate,negative
48,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1,ibuprofen_R,2C9-Substrate,negative
49,CC(=O)C[C@H](c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,Acenocoumarol,-,negative
50,COc1cc(Br)c2oc(C3CCNCC3)cc2c1,Brofaromine,2D6-Substrate,negative
51,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Quercetin,-,negative
52,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
53,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
54,NC(=O)c1cnccn1,Pyrazinamide,1A2-Substrate,negative
55,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,Dexloxiglumide,-,negative
56,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,Flutamide,-,negative
57,CC/C=C\Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_11,3A4-Substrate,negative
58,O=C(O)C=Cc1ccccc1,Bemiparin,SUL-Substrate,negative
59,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,Ketotifen,Methyltransferase-Inducer,negative
60,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
61,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
62,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,Lopinavir,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
63,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,2D6-Substrate,negative
64,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,Cyclobarbital,HLp2-Inducer,negative
65,CN1C(=O)CCC1c1cccnc1,Cotinine,-,negative
66,Cc1c(-c2cnccn2)ssc1=S,Oltipraz,-,negative
67,O=C(O)CCC/C=C\C[C@@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,S_145,2C9-Substrate,negative
68,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
69,Cc1ccccc1,toluene,2E1-Substrate,negative
70,CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,Miocamycin,3A4-Inhibitor,negative
71,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,P450_HFLA-Inhibitor,negative
72,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Substrate,positive
73,C[C@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,Suprofen,-,negative
74,Cn1c(=O)c2c(ncn2C)n(C)c1=O,Caffeine,2E1-Substrate,negative
75,CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2,Granisetron,2D6-Substrate,negative
76,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=C[C@H](O)C[C@@H](O)CC(=O)O,Rosuvastatin,Sodiumbile_acid_cotransporter-Substrate,negative
77,COc1ccc([C@@H](CN(C)C)C2(O)CCCCC2)cc1,Venlafaxine,2D6-Inhibitor,negative
78,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
79,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,Dicoumarol,GST-Inhibitor,negative
80,CC(C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2,Zaltoprofen,-,negative
81,Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,Flucloxacillin,-,negative
82,CCN(CC)CCc1nc(-c2ccccc2)no1,Oxolamine,1B1-Inducer,negative
83,COc1ccc(O)cc1,Mequinol,GST-Inducer,negative
84,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
85,COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,Yohimbine,2D6-Substrate,negative
86,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,retinol,2D6-Substrate,negative
87,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(C=NN5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifampicin,4A11-Inducer,negative
88,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
89,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,Benzethonium,2D6-Substrate,negative
90,CC(C)c1nc(CN(C)C(=O)N[C@@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,Ritonavir,2E1-Inhibitor,negative
91,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
92,C[C@H]1O[C@@H]1P(=O)(O)O,Fosfomycin,GST-Substrate,negative
93,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,P450_HFLA-Substrate,negative
94,CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc1ccc(S(C)=O)cc1,Sulindac,GST-Inducer,negative
95,CC(NC(N)=O)c1cc2ccccc2s1,ABT_66193,2D6-Substrate,negative
96,C/C=C\C,cis_2_butene,2E1-Substrate,negative
97,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
98,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,Benidipine,2D6-Inhibitor,negative
99,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,Leflunomide,-,negative
100,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,UGT-Substrate,positive
101,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
102,CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21,Medazepam,2E1-Inhibitor,negative
103,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@@]21C,lithocholic_acid,3A4-Substrate,negative
104,O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,2E1-Substrate,negative
105,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1,Montelukast,-,negative
106,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,positive
107,CNCCN1C(=O)[C@H](OC(C)=O)[C@H](c2ccc(OC)cc2)Sc2ccccc21,N_desmethyl_diltiazem,3A4-Substrate,negative
108,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C,Ciclesonide,3A4-Substrate,negative
109,CCN(CC)CC#CCOC(=O)[C@@](O)(c1ccccc1)C1CCCCC1,Oxybutynin,2D6-Inhibitor,negative
110,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Glycyrrhizic Acid,P450_HFLA-Inducer,negative
111,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,Chlorphenamine,Methyltransferase-Inducer,negative
112,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl,Etizolam,2C19-Substrate,negative
113,C[C@@H](C(=O)O)c1ccc(C(=O)c2ccccc2)s1,Tiaprofenic Acid,GST-Inhibitor,negative
114,Cc1c2ccccc2c(C)c2c1ccc1ccccc12,DMBA,2E1-Substrate,negative
115,CN[C@@H](C)Cc1ccccc1OC,Methoxyphenamine,2D6-Substrate,negative
116,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,Sulfinpyrazone,-,negative
117,COc1ccc2c(c1)c(CC(=O)NCC(O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,2_hydroxy_indomethacin_phenethylamide,2D6-Substrate,negative
118,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,ellipticine,2D6-Substrate,negative
119,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,UGT-Substrate,positive
120,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,19A-Inhibitor,negative
121,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,19A-Inhibitor,negative
122,Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1,Liarozole,-,negative
123,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Pentoxifylline,GST-Inducer,negative
124,CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32,Vincamine,2E1-Substrate,negative
125,Fc1cccc2c1OC1CNCC1O2,Fluparoxan,-,negative
126,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
127,CN(C)N=Nc1[nH]cnc1C(N)=O,Dacarbazine,2E1-Substrate,negative
128,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
129,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,Cytarabine,Multidrug_resistance_protein_1-Inducer,negative
130,CC(O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,Lisofylline,-,negative
131,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Perphenazine,CP2CI-Substrate,negative
132,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
133,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb12,3A4-Substrate,negative
134,C[C@@H]1Cc2c(Cl)cc(C(=O)N[C@@H](Cc3ccccc3)C(=O)O)c(O)c2C(=O)O1,ochratoxin_A,2C9-Substrate,negative
135,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,Lamotrigine,GST-Inducer,negative
136,Cn1nnc2ccc([C@H](c3ccc(Cl)cc3)n3cncn3)cc21,Vorozole,19A-Inhibitor,negative
137,CN1CCN(C(=O)NC(Cc2ccccc2)C(=O)NC(C=CS(=O)(=O)c2ccccc2)CCc2ccccc2)CC1,K11777,2E1-Substrate,negative
138,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
139,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,Cefadroxil,Solute_carrier_family_15_member_2-Substrate,negative
140,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H]1CCC(=O)N1,Buserelin,19A-Inducer,negative
141,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,CP2CI-Substrate,negative
142,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,Bicalutamide,2D6-Inhibitor,negative
143,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
144,C=C1CC[C@@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,Calcifediol,24A-Substrate,negative
145,O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,Isosorbide Mononitrate,3A4-Substrate,negative
146,CCCCCN(CCCCC)N=O,NN_diamyl_nitrosoamine,2E1-Substrate,negative
147,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,ursodeoxycholic_acid,3A4-Substrate,negative
148,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate,negative
149,O=[N+]([O-])c1ccc(O)cc1,4_nitrophenol,2E1-Substrate,negative
150,COc1ccc(C(c2ccc(OC)cc2)C(Cl)(Cl)Cl)cc1,methoxychlor,2C19-Substrate,negative
151,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,Amodiaquine,2D6-Inhibitor,negative
152,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
153,CC[N+](C)(CC)CCc1c(C(F)(F)F)c2ccc(OC)cc2oc1=O,MeAMFC,2D6-Substrate,negative
154,O=C1CN=C(c2ccccc2F)c2cc(Cl)ccc2N1CC(F)(F)F,2_oxo_quazepam,2C9-Substrate,negative
155,COc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_methoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
156,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,Pyrimethamine,GST-Inhibitor,negative
157,N=C(N)N1CCc2ccccc2C1,Debrisoquine,2D6-Substrate,negative
158,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,Artemisinin,GST-Inhibitor,negative
159,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,Emetine,2D6-Substrate,negative
160,COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Tetrabenazine,2D6-Inhibitor,negative
161,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Escitalopram,2D6-Substrate,negative
162,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,Desloratadine,2D6-Inhibitor,negative
163,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl,Amlodipine,P450_HFLA-Substrate,negative
164,C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,flurbiprofen_R,2C9-Substrate,negative
165,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Idebenone,1A2-Substrate,negative
166,CC(NCC(O)COc1cccc2ccccc12)C(C)(C)C,tert_butyl_propranolol,2D6-Substrate,negative
167,CCCCCCCC/C=C\CCCCCCCC(=O)O,oleic_acid,2E1-Substrate,negative
168,CC(C)C[C@@H](N(C)C)C1(c2ccc(Cl)cc2)CCC1,Sibutramine,-,negative
169,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,Azacitidine,Methyltransferase-Inhibitor,negative
170,CCN[C@H](C)Cc1ccc2c(c1)OCO2,MDE_R,2E1-Substrate,negative
171,COc1ccc(CCNCCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_R,2C8-Substrate,negative
172,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,Apomorphine,SUL-Substrate,negative
173,C[n+]1c2cc(N)ccc2cc2ccc(N)cc21.Cl.Nc1ccc2cc3ccc(N)cc3nc2c1.[Cl-],Acriflavinium Chloride,1B1-Inducer,negative
174,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
175,COC(=O)[C@H](c1ccccc1Cl)N1CCC2SC(=O)C=C2C1,2_oxo_clopidogrel,2D6-Substrate,negative
176,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,13_cis_retinoic_acid,2E1-Substrate,negative
177,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,P450_HFLA-Substrate,negative
178,C=CC1=C(C)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C)c5C=C)C(C)=C4CCC(=O)O)c(CCC(=O)O)c3C.O[Fe+2],Hematin,GST-Inhibitor,negative
179,N#Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(N)c1[S@](=O)C(F)(F)F,fipronil,2C19-Substrate,negative
180,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,UGT-Substrate,positive
181,O=c1[nH]c(=O)n([C@H]2CCCO2)cc1F,Tegafur,2E1-Substrate,negative
182,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,androstenedione,3A4-Substrate,negative
183,CCOc1ccc2ccccc2c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O,Nafcillin,-,negative
184,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
185,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,Mitomycin,1A2-Inducer,negative
186,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,Tramadol,2D6-Inhibitor,negative
187,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,Lumiracoxib,Solute_carrier_family_22_member_6-Inhibitor,negative
188,O=[P@@]1(N(CCCl)CCCl)OCCCN1CCCl,Trofosfamide,-,negative
189,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,Febuxostat,UGT-Substrate,positive
190,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2CC[C@@H]1N2C,Cocaine,GST-Inducer,negative
191,COc1ccc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,Gallopamil,-,negative
192,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Nilotinib,UGT-Inhibitor,negative
193,NC(=O)N1C(=O)C(=C(O)c2cccs2)c2cc(Cl)ccc21,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor,negative
194,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,Trifluoperazine,-,negative
195,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
196,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],Isosorbide Dinitrate,2E1-Inhibitor,negative
197,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,Formoterol,2D6-Substrate,negative
198,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
199,O=C(Cc1cccs1)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12,Cefaloridine,2C8-Substrate,negative
200,CC(N)Cc1ccc(O)cc1,Hydroxyamfetamine,2D6-Substrate,negative
201,C/C=C/c1ccccc1,trans_phenylpropene,2E1-Substrate,negative
202,CC(=O)C1CCC2C3CCC4CC(C)(O)CCC4(C)C3CCC12C,Ganaxolone,-,negative
203,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,Griseofulvin,-,negative
204,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Chlormadinone,-,negative
205,COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)C13,18_methoxy_coronaridine,2D6-Substrate,negative
206,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,Opipramol,2D6-Substrate,negative
207,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,Lynestrenol,2C19-Inducer,negative
208,CC(C)CC(O)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1,bortezomib_M1_M2,2C19-Substrate,negative
209,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Dihydroergotamine,-,negative
210,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,Lu_AA21004,2D6-Substrate,negative
211,CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,Angiotensinamide,Methyltransferase-Inducer,negative
212,ClC(Cl)Cl,Chloroform,2E1-Substrate,negative
213,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
214,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,Emedastine,-,negative
215,CCCCN(CCCC)CC[C@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,Halofantrine,2D6-Inhibitor,negative
216,CN1CCCN=C1C=Cc1cccs1,Pyrantel,2D6-Substrate,negative
217,CC(C)NC[C@H]1CCc2cc(CO)c([N+](=O)[O-])cc2N1,Oxamniquine,2D6-Inhibitor,negative
218,CCN(CC)N=O,NN_diethyl_nitrosoamine,2E1-Substrate,negative
219,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1,Alfentanil,P450_HFLA-Substrate,negative
220,CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Dorzolamide,2E1-Substrate,negative
221,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,17_beta_estradiol,2C9-Substrate,negative
222,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,Sulpiride,-,negative
223,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,Praziquantel,P450_HFLA-Substrate,negative
224,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
225,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
226,CCN(CC)c1cc(C)nc2ncnn12,Trapidil,-,negative
227,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin,-,negative
228,CC(C)(C(=O)c1cccnc1)c1cccnc1,Metyrapone,2E1-Inhibitor,negative
229,Cc1ncc(CO)c(CO)c1O,Pyridoxine (vit B6),Methyltransferase-Inhibitor,negative
230,C1=CCCCC1,cyclohexene,2E1-Substrate,negative
231,CCCCOC(=O)C(=O)Nc1cccc(-c2nn[nH]n2)c1,Tazanolast,-,negative
232,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Pergolide,2D6-Inhibitor,negative
233,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,Anastrozole,UGT-Substrate,positive
234,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Lindane,N_acetyltransferase-Inducer,negative
235,CCCCC/C=C/C/C=C/CCCCCCCC(=O)O,linoleic_acid,2E1-Substrate,negative
236,CCCCCCCCC=CCCCCCCCC(=O)O,Monoethanolamine Oleate,2E1-Substrate,negative
237,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,Albendazole,2D6-Substrate,negative
238,C#CCNC1CCc2ccccc21,Rasagiline,1A2-Substrate,negative
239,O=N[O-],Sodium Nitrite,GST-Inhibitor,negative
240,CN1CCC23CCCCC2C1Cc1ccc(O)cc13,Dextrorphan,2D6-Substrate,negative
241,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,progesterone,2D6-Substrate,negative
242,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
243,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,negative
244,CCCC1(CCc2ccccc2)CC(O)=C(C(CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,Tipranavir,-,negative
245,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)NC1=O)C(C)C,Insulin (human),Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
246,CC[C@H](C(N)=O)N1CCCC1=O,Levetiracetam,GST-Inducer,negative
247,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,Famciclovir,3A4-Substrate,negative
248,CC[C@H](OC(C)=O)C(C[C@H](C)NC)(c1ccccc1)c1ccccc1,norLAAM,2D6-Substrate,negative
249,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,Danazol,19A-Inhibitor,negative
250,Cc1cccc(C)c1,xylene_meta,2E1-Substrate,negative
251,CC(C=CC=C(C)C=CC1=C(C)CCCC1(C)C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C,Betacarotene,GST-Inducer,negative
252,CC(=O)Nc1ccc(O)cc1,Paracetamol,UGT-Substrate,positive
253,COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O,Silymarin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
254,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
255,NC(N)=O,Carbamide,2E1-Inducer,negative
256,Clc1ccc([C@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,Isoconazole,19A-Inhibitor,negative
257,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
258,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,Dipyridamole,Multidrug_resistance_associated_protein_1-Inhibitor,negative
259,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,Phenoxymethylpenicillin,3A4-Inducer,negative
260,CCOc1ccc2c(Cl)cc(=O)oc2c1,4_chloro_7_ethoxycoumarin,2C19-Substrate,negative
261,Cc1nccn1C[C@@H]1CCc2c(c3ccccc3n2C)C1=O,ondansetron,2D6-Substrate,negative
262,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,Sulfaphenazole,2D6-Inhibitor,negative
263,CS(=O)(=O)OC[C@H](O)[C@H](O)COS(C)(=O)=O,Treosulfan,1A2-Inhibitor,negative
264,C[C@@H]1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1,Temafloxacin,1A2-Substrate,negative
265,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,Pipamperone,GST-Inducer,negative
266,CNC(=O)ON=C(C)SC,Methomyl,-,negative
267,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC,Desogestrel,-,negative
268,CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1,Talinolol,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
269,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O,Teicoplanin,SUL-Substrate,negative
270,Nc1ccc(C(=O)NCC(=O)O)cc1,Aminohippuric Acid,Solute_carrier_family_22_member_6-Substrate,negative
271,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,negative
272,CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C,Etretinate,19A-Inhibitor,negative
273,CCCNCc1cc(=O)oc2cc(OC)ccc12,PMAMC,2D6-Substrate,negative
274,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Pimecrolimus,3A4-Substrate,negative
275,CCN(CC)C(=O)C(C#N)=Cc1cc(O)c(O)c([N+](=O)[O-])c1,Entacapone,2E1-Inhibitor,negative
276,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Cholic Acid,SUL-Substrate,negative
277,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
278,COc1ccc(OC(F)(F)F)cc1CN,cp_677_623,2E1-Substrate,negative
279,CC[C@@]1(c2ccccc2)NC(=O)N(C)C1=O,Mephenytoin,CP2CI-Substrate,negative
280,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,Nimesulide,2C9-Inhibitor,negative
281,O=C1C=C2CN(C(C(=O)C3CC3)c3ccccc3F)CCC2S1,R_95913,2D6-Substrate,negative
282,[Li],Lithium,Solute_carrier_family_12_member_2-Inducer,negative
283,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,Proadifen,-,negative
284,Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,Thiamine (vit B1),P450_HP-Inducer,negative
285,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,Diosmectite,1B1-Inhibitor,negative
286,CC1=CC(=O)[C@@H]2C[C@H]1C2(C)C,Levoverbenone,2B6-Substrate,negative
287,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,Topotecan,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
288,CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1,OSU_6162,2D6-Substrate,negative
289,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Lovastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
290,CN1C2CCC1CC(NC(=O)c1cc(Cl)cc3c1OC(C)(C)C3)C2,Zatosetron,-,negative
291,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,Vecuronium,Methyltransferase-Inhibitor,negative
292,NC[C@H](O)c1ccc(O)cc1,Octopamine,2D6-Substrate,negative
293,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,Cefepime,Solute_carrier_family_22_member_5-Inhibitor,negative
294,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O,ABT_761,2E1-Substrate,negative
295,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Aceclofenac,-,negative
296,O=C(O)C/C=C/C[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,bisnor,3A4-Substrate,negative
297,CN(C)N=O,NN_dimethyl_nitrosoamine,2E1-Substrate,negative
298,Nc1nc(C(=CCC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@@H]23)cs1,Ceftibuten,Solute_carrier_family_15_member_1-Substrate,negative
299,COC(=O)c1c(C)nc(C)c(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)c1-c1cccc([N+](=O)[O-])c1,barnidipine_M8,3A4-Substrate,negative
300,CCc1cccc2cc([C@H](O)CNC(C)(C)C)oc12,bufuralol_R,2D6-Substrate,negative
301,Cc1cc(=O)oc2cc(O)ccc12,Hymecromone,UGT-Substrate,positive
302,Nc1c2c(nc3ccccc13)CCCC2,Tacrine,GST-Substrate,negative
303,O=C1OC(c2ccc(O)c(S(=O)(=O)O)c2)(c2ccc(O)c(S(=O)(=O)O)c2)c2c(Br)c(Br)c(Br)c(Br)c21,Sulfobromophthalein,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
304,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
305,CCC1(c2ccccc2)C(=O)NCNC1=O,Primidone,-,negative
306,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,pregnenolone,2D6-Substrate,negative
307,COc1c2occc2cc2ccc(=O)oc12,Methoxsalen,-,negative
308,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,Etoricoxib,2E1-Inhibitor,negative
309,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
310,COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC,Oxypertine,Canalicular_multispecific_organic_anion_transporter_2-Inducer,negative
311,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,tolterodine,2D6-Substrate,negative
312,CC(C)(C)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Terfenadine,P450_HFLA-Substrate,negative
313,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
314,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,Trimethoprim,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
315,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
316,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,negative
317,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,Celecoxib,SUL-Inhibitor,negative
318,CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,Olopatadine,-,negative
319,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,Pentazocine,2D6-Substrate,negative
320,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Vernakalant,2D6-Substrate,negative
321,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
322,c1ccccc1,Benzene,-,negative
323,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
324,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[C@@H](C(=O)N(C)C)N3)[C@H](C)[C@H]12,Meropenem,Solute_carrier_family_22_member_6-Substrate,negative
325,[Se],Selenium Compounds,Methyltransferase-Inhibitor,negative
326,O=C([O-])O,Sodium Bicarbonate,Electroneutral_sodium_bicarbonate_exchanger_1-Substrate,negative
327,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,Bosentan,Sodiumbile_acid_cotransporter-Inhibitor,negative
328,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,Benzydamine,2E1-Substrate,negative
329,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,Captopril,Methyltransferase-Substrate,negative
330,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Amitriptyline,UGT-Substrate,positive
331,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C=O)C[C@@H]21,11_oxo_delta_8_tetrahydro_cannabinol,2D6-Substrate,negative
332,O[C@H](CBr)[C@@H](O)[C@H](O)[C@H](O)CBr,Mitobronitol,1B1-Inducer,negative
333,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,Ipriflavone,2E1-Inducer,negative
334,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,Sultiame,N_acetyltransferase-Inducer,negative
335,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
336,CC=CC[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,Ciclosporin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
337,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,Ranitidine,2D6-Substrate,negative
338,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C,Metamizole Sodium,GST-Inducer,negative
339,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,Ciprofloxacin,2E1-Inducer,negative
340,CCCCCC,hexane,2E1-Substrate,negative
341,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
342,CCNC(C)Cc1ccccc1,N_ethyl_amphetamine,2D6-Substrate,negative
343,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
344,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
345,C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1,Bupropion,2E1-Substrate,negative
346,ClC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl,Dieldrin,-,negative
347,CC[C@H](C)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,Teriparatide,24A-Inhibitor,negative
348,C=C[C@@H](N)CCC(=O)O,Vigabatrin,Proton_coupled_amino_acid_transporter_1-Substrate,negative
349,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
350,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Retigabine,1A1-Substrate,negative
351,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
352,CN1CCN(CCCN2c3ccccc3Sc3ccccc32)CC1,Perazine,2E1-Substrate,negative
353,CC(C)(C)N1CCC(c2ccccc2)(c2ccccc2)CC1,Budipine,2D6-Inhibitor,negative
354,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer,negative
355,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
356,CCC(=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1,methadone_R,2D6-Substrate,negative
357,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
358,CN(C)c1ccc(C2CC3(C)C(CCC3(O)C=CCO)C3CCC4=CC(=O)CCC4=C23)cc1,Lilopristone,-,negative
359,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
360,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,Clonazepam,-,negative
361,CC(C)(Oc1ccc([C@H]2CC2(Cl)Cl)cc1)C(=O)O,Ciprofibrate,4A11-Inducer,negative
362,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,testosterone,2C19-Substrate,negative
363,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,Clomifene,19A-Inhibitor,negative
364,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,UGT-Substrate,positive
365,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
366,Cn1cnc2c1c(=O)n(CC1CCCO1)c(=O)n2C,theobromine_deriv_9,3A4-Substrate,negative
367,CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Hydroquinidine,-,negative
368,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,Mefloquine,19A-Inhibitor,negative
369,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
370,O=C(c1cccs1)c1ccc(O)c(Cl)c1Cl,tienilic_acid_deriv_1,2C9-Substrate,negative
371,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
372,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,Mibefradil,P450_HFLA-Inhibitor,negative
373,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
374,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C=O)C(C)(C)CCC1,9_cis_retinal,2C19-Substrate,negative
375,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,SUL-Substrate,negative
376,OC(c1ccccc1)(c1ccccc1)C1CCNCC1,Azacyclonol,-,negative
377,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,Aminophenazone,CP2CI-Substrate,negative
378,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
379,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Levacetylmethadol,19A-Substrate,negative
380,Nc1nc(=O)c(Br)c(-c2ccccc2)[nH]1,bropirimine,1A2-Substrate,negative
381,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,Estriol,UGT-Substrate,positive
382,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
383,C=CC[C@]1(O)CC[C@H]2[C@H]3CCC4=CCCC[C@H]4[C@@H]3CC[C@]21C,Allylestrenol,3A4-Substrate,negative
384,Cc1cnc2ccc3c(nc(N)n3C)c2n1,2_amino_3_8_dimethylimidazo_4_5_f_quinoxaline,1A2-Substrate,negative
385,CC(C)NC[C@H](O)c1ccc(O)c(O)c1,Isoprenaline,19A-Inducer,negative
386,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
387,Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,Cefazolin,Solute_carrier_family_22_member_6-Substrate,negative
388,NC(=O)c1c(Cl)c(-c2cccnc2)n2c1CCCC2,CMV_423,2C9-Substrate,negative
389,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
390,COc1ccc2[nH]c([S@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_R,2C19-Substrate,negative
391,COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1,Fluvoxamine,2E1-Substrate,negative
392,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
393,C[C@@](N)(Cc1ccc(O)c(O)c1)C(=O)O,Methyldopa (levorotatory),GST-Inhibitor,negative
394,CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate,negative
395,CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,Azelastine,2E1-Inhibitor,negative
396,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,Morphine,2D6-Substrate,negative
397,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
398,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
399,O=[As]1=[As](=O)O1,Arsenic Trioxide,1B1-Inhibitor,negative
400,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2D6-Inhibitor,negative
401,CCCN1CCCC2Cc3nc(N)ncc3CC21,Quinelorane,-,negative
402,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
403,CC(C)=C[C@@H]1[C@@H](C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C,Tetramethrin,3A4-Inducer,negative
404,C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,SNI_2011_R_R,2D6-Substrate,negative
405,CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,Delapril,-,negative
406,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
407,CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,Efonidipine,-,negative
408,COc1ccc2c(CN(C)C)cc(=O)oc2c1,DiMMAMC,2D6-Substrate,negative
409,NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,Liothyronine,-,negative
410,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,Sorafenib,UGT-Inhibitor,negative
411,CC12C=CC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Boldenone,-,negative
412,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
413,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
414,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,Prazepam,3A4-Substrate,negative
415,C=CCSSCC=C,diallylsulfide,2E1-Substrate,negative
416,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,Astemizole,P450_HFLA-Substrate,negative
417,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,Mepacrine,Methyltransferase-Inhibitor,negative
418,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,Felodipine,P450_HFLA-Substrate,negative
419,c1cnc2cc3c(cc2n1)[C@H]1CNC[C@@H]3C1,Varenicline,Methyltransferase-Inhibitor,negative
420,C[C@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,Cyamemazine,2C9-Substrate,negative
421,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
422,CNC(=O)Oc1cccc2ccccc12,carbaryl,2E1-Substrate,negative
423,C#CCC12CCC(=O)C=C1CCC1C3CCC(=O)C3(C)CCC12,Plomestane,-,negative
424,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,Delavirdine,2D6-Inhibitor,negative
425,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
426,CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,Drospirenone,-,negative
427,Cc1ccc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)nc1,Glipizide,-,negative
428,O=C(O)c1ccccc1O,Salicylic Acid,2E1-Inducer,negative
429,C[C@H](c1cc2ccccc2s1)N(O)C(N)=O,zileuton_R,2E1-Substrate,negative
430,CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1,rosiglitazone_R,2C9-Substrate,negative
431,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,CP2CI-Substrate,negative
432,CCC(=O)O[C@@H](O[P@@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,Fosinopril,Solute_carrier_family_15_member_2-Substrate,negative
433,Clc1ccc([C@@H](Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,Tioconazole,19A-Inhibitor,negative
434,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,Trimetrexate,-,negative
435,C#CC1(O)CCC2C3CCc4cc(OC)ccc4C3CCC21C,Mestranol,-,negative
436,c1ccc2c(c1)ccc1nc3ccc4ccccc4c3cc12,dibenzacridine,1A2-Substrate,negative
437,COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,DDB_aka_BDD,2C9-Substrate,negative
438,C[C@@H](CN1c2ccccc2Sc2ccccc21)N(C)C,Promethazine,2D6-Inhibitor,negative
439,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Saquinavir,P450_HFLA-Substrate,negative
440,CCc1cccc2cc(C(O)CNC(C)(C)C)oc12,Bufuralol,2D6-Substrate,negative
441,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,muraglitazar,2E1-Substrate,negative
442,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,2D6-Inhibitor,negative
443,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,Nefazodone,P450_HFLA-Inhibitor,negative
444,COc1ccc(NC(C)=O)cc1,O_methyl_acetaminophen,1A2-Substrate,negative
445,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,Amobarbital,Coumarin_7_hydroxylase-Inducer,negative
446,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
447,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,Tirilazad,-,negative
448,COc1cc2nc(N3CCN(C(=O)[C@@H]4COc5ccccc5O4)CC3)nc(N)c2cc1OC,Doxazosin,2D6-Substrate,negative
449,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,Idarubicin,2D6-Inhibitor,negative
450,OCCN1CCN(CCC=C2c3ccccc3Sc3ccc(Cl)cc32)CC1,Zuclopenthixol,2D6-Substrate,negative
451,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,Metandienone,3A4-Substrate,negative
452,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Troleandomycin,CP2CI-Inhibitor,negative
453,CC1=CC[C@H]2[C@@H](C1)C2(C)C,delta_3_carene,2D6-Substrate,negative
454,CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12,Maprotiline,2D6-Substrate,negative
455,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,fluvoxamine,2D6-Substrate,negative
456,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Prochlorperazine,2D6-Substrate,negative
457,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Gemcitabine,Multidrug_resistance_associated_protein_5-Inducer,negative
458,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
459,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,Remacemide,-,negative
460,CC(CF)NCC(O)COc1cccc2ccccc12,fluoro_propranolol,2D6-Substrate,negative
461,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Doxycycline,-,negative
462,CNC(=NC#N)NCCSCc1nc[nH]c1C,Cimetidine,2E1-Inhibitor,negative
463,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,Aripiprazole,P450_HFLA-Substrate,negative
464,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,UGT-Substrate,positive
465,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
466,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,Toremifene,-,negative
467,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,Tazarotene,2C8-Substrate,negative
468,CNCCCN1c2ccccc2CCc2ccccc21,Desipramine,2E1-Inhibitor,negative
469,CC(CO)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,ipriflavone_M4,1A2-Substrate,negative
470,CCC(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C,Promegestone,SUL-Inducer,negative
471,COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,eupatilin,2E1-Substrate,negative
472,CC(C)(Oc1ccc(Cl)cc1)C(=O)O,Clofibric acid,-,negative
473,Cc1c[nH]c2ccccc12,3_methylindole,2E1-Substrate,negative
474,NC(=O)c1ccccc1O,Salicylamide,1B1-Inhibitor,negative
475,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Simvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
476,C=CCOc1ccccc1OC[C@H](O)CNC(C)C,Oxprenolol,2D6-Inhibitor,negative
477,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
478,C[S+](CC[C@H](N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,Ademetionine,2E1-Inhibitor,negative
479,CCC[C@@H]1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,Azapropazone,-,negative
480,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,Bortezomib,2D6-Inhibitor,negative
481,NNc1nnc(NN)c2ccccc12,Dihydralazine,-,negative
482,CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,Emivirine,-,negative
483,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,Moclobemide,Methyltransferase-Inhibitor,negative
484,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,Mebendazole,-,negative
485,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
486,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
487,NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,Famotidine,-,negative
488,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,4A11-Inducer,negative
489,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
490,CCN(CC)C(=S)[S-].[Na+],Ditiocarb sodium,-,negative
491,CNC[C@H](O)c1ccc(O)c(O)c1,Epinephrine,UGT-Substrate,positive
492,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,Indinavir,UGT-Substrate,positive
493,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Glucagon,GST-Inhibitor,negative
494,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,Dofetilide,-,negative
495,CCOc1ccc2ccc(=O)oc2c1,7_ethoxy_coumarin,2E1-Substrate,negative
496,CC(C)N(CC[C@](C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,Disopyramide,-,negative
497,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
498,C[C@@H](O)C(=O)O,Milchsäure,Monocarboxylate_transporter_1-Substrate,negative
499,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
500,CCCc1cc(=O)[nH]c(=S)[nH]1,Propylthiouracil,GST-Inhibitor,negative
501,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,P450_HFLA-Substrate,negative
502,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,Tamsulosin,2D6-Substrate,negative
503,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,NE_100,2D6-Substrate,negative
504,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digitoxin,UGT-Substrate,positive
505,CS(=O)(=O)OCCCCOS(C)(=O)=O,Busulfan,GST-Substrate,negative
506,CCC1(CC)C(=O)NC[C@@H](C)C1=O,Methyprylon,2D6-Substrate,negative
507,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vindesine,-,negative
508,C[C@H](C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,Pirprofen,UGT-Substrate,positive
509,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate,negative
510,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,Clotrimazole,19A-Inhibitor,negative
511,c1cnc(N2CCNCC2)nc1,1_PP,2D6-Substrate,negative
512,N=O,Nitric Oxide,GST-Inducer,negative
513,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,negative
514,NC(=O)N1c2ccccc2C=Cc2ccccc21,Carbamazepine,P450_HFLA-Substrate,negative
515,CCC1(c2ccncc2)CCC(=O)NC1=O,Rogletimide,-,negative
516,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminoglutethimide,-,negative
517,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,harmaline,2D6-Substrate,negative
518,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,Ascorbic Acid (vit C),GST-Inhibitor,negative
519,Cc1ccc(C(=O)[C@H](C)CN2CCCCC2)cc1,Tolperisone,2D6-Substrate,negative
520,COc1ccc2c(c1)c(CC(=O)NCCc1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,indomethacin_phenethylamide,2D6-Substrate,negative
521,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
522,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Fluconazole,CP2CI-Inhibitor,negative
523,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Terconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
524,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,Buspirone,P450_HFLA-Substrate,negative
525,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
526,[Cl-].[K+],Potassium Chloride,Solute_carrier_family_12_member_2-Substrate,negative
527,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSCCC(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,Desmopressin,Solute_carrier_family_12_member_1-Inducer,negative
528,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,Ibuprofen,GST-Inducer,negative
529,CCN(CC)C(=O)N1CCN(C)CC1,Diethylcarbamazine,GST-Inducer,negative
530,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
531,OO,Hydrogen Peroxide,GST-Inhibitor,negative
532,COc1ccc2c3c1O[C@H]1C(OC(C)=O)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341,Thebacon,2D6-Substrate,negative
533,O=c1ccc2nc3ccc(OCc4ccccc4)cc3oc-2c1,benzyl_oxy_resorufin,2D6-Substrate,negative
534,COc1ccc([C@H](CC(=O)O)N2CCN(CCCc3ccc4c(n3)NCCC4)C2=O)cn1,compound_A,2D6-Substrate,negative
535,Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,DMXAA,1A2-Substrate,negative
536,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,Pemetrexed,Proton_coupled_folate_transporter-Substrate,negative
537,O=[N+]([O-])c1cncn1CCN1CCOCC1,Nimorazole,-,negative
538,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,apigenin,1A2-Substrate,negative
539,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
540,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
541,CCNCc1cc(=O)oc2cc(OC)ccc12,EMAMC,2D6-Substrate,negative
542,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,Oxcarbazepine,-,negative
543,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,Tamoxifen,UGT-Substrate,positive
544,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
545,C[C@@H]1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23,Flumequine,2E1-Inhibitor,negative
546,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,Nilutamide,-,negative
547,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
548,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,Quinapril,Solute_carrier_family_15_member_2-Inhibitor,negative
549,O=c1[nH]cc(F)c(=O)[nH]1,Fluorouracil,-,negative
550,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
551,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,4A11-Inducer,negative
552,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,Clobazam,CP2CI-Substrate,negative
553,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,negative
554,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,Fosphenytoin,-,negative
555,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,Norfloxacin,P450_HFLA-Inhibitor,negative
556,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,Flurazepam,2E1-Inhibitor,negative
557,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
558,N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O,Oxitriptan,Proton_coupled_amino_acid_transporter_1-Inhibitor,negative
559,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,Norethisterone,P450_HFLA-Substrate,negative
560,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
561,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
562,Nc1nc2cc(Cl)ccc2o1,Zoxazolamine,-,negative
563,O=C(O)c1cccnc1,Nicotinic Acid,2D6-Inhibitor,negative
564,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Beclometasone,-,negative
565,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,sibutramine,2C19-Substrate,negative
566,CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1,Propafenone,2D6-Inhibitor,negative
567,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,Naproxen,UGT-Substrate,positive
568,Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,Triprolidine,2D6-Inhibitor,negative
569,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
570,OCC(O)CO,Glycerol,2E1-Inducer,negative
571,Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,Raltegravir,UGT-Substrate,positive
572,CCCC(C)(COC(N)=O)COC(N)=O,Meprobamate,UGT-Substrate,positive
573,CCC(C)CCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_7,3A4-Substrate,negative
574,CCN(CC)C(=S)SC,DDTC_Me,2E1-Substrate,negative
575,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,Decitabine,Methyltransferase-Inhibitor,negative
576,C[C@@H](NC(=Nc1ccncc1)NC#N)C(C)(C)C,Pinacidil,2D6-Substrate,negative
577,c1ccc2c(c1)ccc1ccccc12,phenanthrene,1A2-Substrate,negative
578,CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,ranitidine,2D6-Substrate,negative
579,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
580,CCN(CC)CCOC(=O)c1ccc(N)cc1,Procaine,Methyltransferase-Inhibitor,negative
581,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12,Corticosterone,-,negative
582,N[C@@H]1CCCC[C@H]1N,Oxaliplatin,2E1-Substrate,negative
583,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
584,NC(=O)c1c(Cl)c(-c2cccnc2)n2c1C(O)CCC2,RPR_127025,3A4-Substrate,negative
585,CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,phenprocoumon_S,2C19-Substrate,negative
586,CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,Clofazimine,-,negative
587,CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1,Bisoprolol,2D6-Substrate,negative
588,CC(C)NCCCOc1cccc2ccccc12,deshydroxy_propranolol,2D6-Substrate,negative
589,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,simvastatin_hydroxy_acid,2C8-Substrate,negative
590,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Teniposide,-,negative
591,CCCCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_butylamphetamine,2D6-Substrate,negative
592,Fc1cccc(CCN2CCN(CCCc3c[nH]c4ccc(-n5cnnc5)cc34)CC2)c1,L_775_606,2C8-Substrate,negative
593,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,Estrone,4A11-Substrate,negative
594,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone,-,negative
595,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,Minaprine,2D6-Substrate,negative
596,O=NN1CCCC1,N_nitroso_pyrrolidine,2E1-Substrate,negative
597,O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1,Fenbufen,Multidrug_resistance_protein_1-Inducer,negative
598,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Ergoloid Mesylates,Solute_carrier_organic_anion_transporter_family_member_2B1-Inhibitor,negative
599,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
600,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine,2D6-Inhibitor,negative
601,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,Almotriptan,2D6-Substrate,negative
602,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,Cisapride,GST-Inducer,negative
603,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D3,3A4-Substrate,negative
604,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)n2C1,licofelone_M1,2C8-Substrate,negative
605,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer,negative
606,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
607,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,UGT-Substrate,positive
608,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
609,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
610,O=C(CO)NCCCOc1cccc(CN2CCCCC2)c1,Roxatidine,2D6-Substrate,negative
611,CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O,Tretinoin,Solute_carrier_family_28_member_3-Inducer,negative
612,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1,Thalidomide,CP2CI-Substrate,negative
613,C=CC1CO1,butadienemonoxide,2E1-Substrate,negative
614,CCc1cccc2c3c([nH]c12)[C@](CC)(CC(=O)O)OCC3,Etodolac,UGT-Substrate,positive
615,CN(C)C(=O)Oc1ccc[n+](C)c1,Pyridostigmine,3A4-Inducer,negative
616,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
617,COc1ccc(CCNCCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_S,2C8-Substrate,negative
618,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vincristine,P450_HFLA-Substrate,negative
619,COc1ccc(-c2cc(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]5O)[C@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O,Diosmin,Methyltransferase-Inhibitor,negative
620,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O,tamarixetin,2C9-Substrate,negative
621,CCN(C)N=O,NN_methyl_ethyl_nitrosoamine,2E1-Substrate,negative
622,CCCCCOc1ccc2ccc(=O)oc2c1,7_pentoxy_coumarin,3A4-Substrate,negative
623,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
624,FC(F)O[C@@H](Cl)C(F)(F)F,Isoflurane,2E1-Substrate,negative
625,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1,Torasemide,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
626,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
627,Cc1ccc(O)c([C@@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,Tolterodine,2D6-Substrate,negative
628,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,Clevidipine,2C9-Inhibitor,negative
629,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
630,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
631,CNC(=S)Oc1cc(C)c(SC)c(C)c1,methiocarb,2D6-Substrate,negative
632,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Quinine,-,negative
633,CC(C)CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_6,3A4-Substrate,negative
634,C=CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_12,3A4-Substrate,negative
635,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
636,COc1ccc([C@H](CN(C)C)C2(O)CCCCC2)cc1,venlafaxine_R,2D6-Substrate,negative
637,CCC[N@@+]12[C@H]3C[C@@]45c6ccccc6N(C)[C@H]4[C@@H]1C[C@H]([C@@H]3[C@H]5O)[C@H](CC)[C@H]2O,Prajmaline,2D6-Substrate,negative
638,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
639,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,Ivermectin,-,negative
640,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
641,CN1C(=O)[C@](C)(C2=CCCCC2)C(=O)N=C1O,Hexobarbital,-,negative
642,COc1ccc(C(c2ccc(O)c(O)c2)C(Cl)(Cl)Cl)cc1,catechol_methoxychlor,2D6-Substrate,negative
643,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,Amoxapine,2D6-Substrate,negative
644,C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,Masoprocol,Arachidonic_acid_epoxygenase-Inhibitor,negative
645,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
646,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H](O)[C@@]1(C)O,erythromycin,3A4-Substrate,negative
647,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,Phenolphthalein,UGT-Substrate,positive
648,CC(=O)[C@H]1CC[C@H]2[C@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@@H]3[C@H](O)C[C@]12C,Medrysone,2E1-Inhibitor,negative
649,Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,Folic Acid,2E1-Substrate,negative
650,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,Rupatadine,-,negative
651,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
652,CC1COC2(c3ccccc3Cl)c3cc(Cl)ccc3NC(=O)CN12,Mexazolam,-,negative
653,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],Dipotassium clorazepate,-,negative
654,C=CC#N,acrylonitrile,2E1-Substrate,negative
655,CCNc1ncn(Cc2ccc(OC)c(OC3CCCC3)c2)c2nc(C(C)C)nc1-2,V_11294,2D6-Substrate,negative
656,CCOCC,Diethyl Ether,2E1-Inducer,negative
657,CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(C(C)=O)c1,Celiprolol,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
658,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-],Aranidipine,-,negative
659,Clc1cccc(N2CCNCC2)c1,m-Chlorophenylpiperazine,2D6-Substrate,negative
660,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,Enoxacin,-,negative
661,C#C[C@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@H]3C(=C)C[C@]21CC,Etonogestrel,-,negative
662,Cc1ccccc1C,xylene_ortho,2E1-Substrate,negative
663,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
664,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
665,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
666,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
667,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
668,O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12,rutaecarpine,2E1-Substrate,negative
669,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,bortezomib,2D6-Substrate,negative
670,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,Diazepam,CP2CI-Substrate,negative
671,CC[C@]1(C)CC(=O)NC1=O,Ethosuximide,2E1-Substrate,negative
672,OCc1cc([C@@H](O)CNCCCCCCOCCCCc2ccccc2)ccc1O,Salmeterol,P450_HFLA-Substrate,negative
673,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
674,COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,ezlopitant,2D6-Substrate,negative
675,CCNc1nc(NC(C)C)nc(SC)n1,ametryne,2C19-Substrate,negative
676,CN(CC(=O)O)C(=N)NP(=O)(O)O,Fosfocreatine,Methyltransferase-Inhibitor,negative
677,COCCCOc1ccnc(CC(=O)c2nc3ccccc3[nH]2)c1C,Rabeprazole,-,negative
678,Oc1ccccc1,Phenol,UGT-Substrate,positive
679,Cc1cc(NC(=O)NC(=O)c2ccccc2N(C)C)ccc1Oc1ncc(Br)cn1,benzoyl_phenyl_urea,2D6-Substrate,negative
680,COc1cc([C@H]2c3cc4c(cc3C[C@@H]3COC(=O)[C@H]32)OCO4)cc(OC)c1OC,Podophyllotoxin,2C19-Substrate,negative
681,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC,Etoperidone,2D6-Substrate,negative
682,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,Quazepam,2C19-Substrate,negative
683,FC(F)OC(F)(F)[C@H](F)Cl,Enflurane,2E1-Substrate,negative
684,CN1CCN(C(=O)O[C@@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,Zopiclone,2E1-Substrate,negative
685,O=C(c1cccs1)c1ccc(OCCCO)c(Cl)c1Cl,tienilic_acid_deriv_3,2C19-Substrate,negative
686,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,Timoprazole,-,negative
687,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,Chinin,GST-Inhibitor,negative
688,CN[C@@H](C)[C@H](O)c1ccccc1,Ephedrin,SUL-Substrate,negative
689,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,positive
690,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Mitiglinide,UGT-Substrate,positive
691,CCC(=O)O[C@@H]1CC(=O)O[C@@H](C)CC=CC=C[C@@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@H](OC(=O)CC)[C@@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H]1OC,Midecamycin,-,negative
692,CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12,Pindolol,2D6-Substrate,negative
693,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,Exemestane,19A-Inhibitor,negative
694,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
695,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],Nifedipine,2E1-Inhibitor,negative
696,Nc1nc(NC2CC2)c2ncn([C@@H]3C=C[C@H](CO)C3)c2n1,Abacavir,UGT-Substrate,positive
697,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
698,COC(C)(C)C,methyl_tert_butyl_ether,2E1-Substrate,negative
699,COSc1cn(C)c2cc(F)ccc2c1=O,Flosequinan,-,negative
700,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
701,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,UGT-Substrate,positive
702,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,Tiagabine,2D6-Substrate,negative
703,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,Lamivudine,Solute_carrier_family_22_member_1-Substrate,negative
704,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,Ebastine,-,negative
705,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
706,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
707,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,Zotepine,2D6-Substrate,negative
708,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@@H]3C[C@@H]12,Tetracycline,GST-Inhibitor,negative
709,CC(C)Cn1cnc2c(N)nc3ccccc3c21,Imiquimod,-,negative
710,CCOc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Ethylmorphine,P450_HFLA-Substrate,negative
711,CN(C)CCN(Cc1ccccc1)c1ccccn1,Tripelennamine,2D6-Inhibitor,negative
712,COP(=S)(OC)SCn1nnc2ccccc2c1=O,azinphosmethyl,2C19-Substrate,negative
713,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,Olanzapine,GST-Inducer,negative
714,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
715,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=N[C@H]1O,Oxazepam,UGT-Substrate,positive
716,CCOC(C)(C)C,ethyl_tert_butyl_ether,2E1-Substrate,negative
717,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,Etacrynic Acid,GST-Substrate,negative
718,CN(C)c1ccc(C2CC3(C)C(CCC3(O)CCCO)C3CCC4=CC(=O)CCC4=C23)cc1,Onapristone,-,negative
719,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
720,C[C@@H](N)[C@@H](O)c1ccccc1,Phenylpropanolamine,1A2-Inhibitor,negative
721,CN1C(=O)C[C@H](c2ccccc2)C1=O,Phensuximide,-,negative
722,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
723,CCOc1ccc2cc(C#N)c(=O)oc2c1,3_cyano_7_ethoxycoumarin,2E1-Substrate,negative
724,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Dasatinib,UGT-Inhibitor,negative
725,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,Flurbiprofen,UGT-Substrate,positive
726,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
727,C=CC(C)(O)CCC=C(C)C,linalool,2D6-Substrate,negative
728,CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,mesoridazine,2D6-Substrate,negative
729,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1,kaempferide,2C9-Substrate,negative
730,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
731,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,Calcitriol,SUL-Inducer,negative
732,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
733,CCCC(CCC)C(=O)O,Valproic Acid,UGT-Substrate,positive
734,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,buprenorphine,2C8-Substrate,negative
735,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
736,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,Melphalan,GST-Substrate,negative
737,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
738,CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1c1cccc([N+](=O)[O-])c1,Niludipine,-,negative
739,CC(C)C(C)NCC(O)COc1cccc2ccccc12,isopropyl_propranolol,2D6-Substrate,negative
740,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,Cladribine,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
741,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
742,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,Yohimbin,2D6-Inhibitor,negative
743,CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC,NO_1886,2C8-Substrate,negative
744,C[C@H](S)C(=O)NCC(=O)O,Tiopronin,2E1-Inhibitor,negative
745,C[C@@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,suprofen_R,2C9-Substrate,negative
746,NCC(=O)O,Glycine,GST-Inducer,negative
747,CNCCC=C1c2ccccc2CCc2ccccc21,Nortriptyline,2E1-Inhibitor,negative
748,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
749,CC(C)c1cccc(C(C)C)c1O,Propofol,CP2CI-Substrate,negative
750,C=Cc1ccccc1,styrene,2E1-Substrate,negative
751,Cc1cccc(Nc2ccccc2C(=O)O)c1C,Mefenamic acid,-,negative
752,CCCc1ccc2ccccc2n1,2n_propylquinoline,2E1-Substrate,negative
753,CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Fosamprenavir,2C19-Inhibitor,negative
754,COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_S,2C19-Substrate,negative
755,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Cetirizine,-,negative
756,OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,Inosine,Solute_carrier_family_28_member_3-Inhibitor,negative
757,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,Estazolam,3A4-Substrate,negative
758,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
759,N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,Amiloride,Solute_carrier_family_22_member_1-Inhibitor,negative
760,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,Dexmedetomidine,2D6-Inhibitor,negative
761,CCCCC[C@H](O)C=C[C@@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,Alprostadil,Multidrug_resistance_associated_protein_4-Substrate,negative
762,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Imatinib,P450_HFLA-Substrate,negative
763,NNCCc1ccccc1,Phenelzine,P450_HFLA-Inhibitor,negative
764,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
765,C=CC1(C)CO1,isoprene_epoxide_1,2E1-Substrate,negative
766,CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Fexofenadine,2D6-Inhibitor,negative
767,CC(C)CCON=O,Amyl Nitrite,GST-Substrate,negative
768,CCCCCCCCC,nonane,2E1-Substrate,negative
769,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
770,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Pimozide,2E1-Inhibitor,negative
771,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor,negative
772,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1,Carbinoxamine,2E1-Substrate,negative
773,O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,Efavirenz,2D6-Inhibitor,negative
774,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
775,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
776,CCN[C@@H]1C[C@H](N)[C@@H](O[C@@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,Netilmicin,N_acetyltransferase-Substrate,negative
777,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)C=CC=CC[C@@H](C)OC(=O)C[C@H]1OC(C)=O,Josamycin,-,negative
778,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,Valdecoxib,2D6-Substrate,negative
779,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,Tinidazole,19A-Inhibitor,negative
780,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,Nandrolone,19A-Substrate,negative
781,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
782,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,Saxagliptin,3A4-Substrate,negative
783,CCN1C(=O)N[C@@H](c2ccccc2)C1=O,Ethotoin,-,negative
784,NC(N)=NN=Cc1c(Cl)cccc1Cl,Guanabenz,-,negative
785,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,Dinoprostone,19A-Inducer,negative
786,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,Triclosan,SUL-Inhibitor,negative
787,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc([N+](=O)[O-])c1,Nilvadipine,2E1-Substrate,negative
788,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,Reserpine,-,negative
789,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cinnarizine,2D6-Substrate,negative
790,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,Amsacrine,2D6-Substrate,negative
791,CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],Pyridostigmine bromide,-,negative
792,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Hydroxyprogesterone,UGT-Substrate,positive
793,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
794,CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Methadone,CP2CI-Substrate,negative
795,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,Arbekacin,N_acetyltransferase-Substrate,negative
796,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Diclofenac,CP2CI-Substrate,negative
797,Cc1ncc([N+](=O)[O-])n1C[C@H](O)CCl,Ornidazole,P450_HFLA-Substrate,negative
798,O=C(O)Cc1cc(O)ccc1Nc1c(Cl)cccc1Cl,5_hydroxy_diclofenac,2C9-Substrate,negative
799,COc1ccc(CC(C)N)cc1,4_methoxy_amphetamine,2D6-Substrate,negative
800,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
801,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
802,COCCCOc1ccnc(CSc2nc3ccccc3[nH]2)c1C,rabeprazole_thioether,2E1-Substrate,negative
803,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,Levothyroxine Sodium,3A4-Substrate,negative
804,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,Benoxaprofen,1A2-Inducer,negative
805,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,Benzbromarone,-,negative
806,O=NN1CCC[C@H]1c1cccnc1,N_nitroso_nornicotine,3A4-Substrate,negative
807,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,UGT-Substrate,positive
808,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,Zalcitabine,P450_HFLA-Substrate,negative
809,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,Tasosartan,-,negative
810,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-,negative
811,Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,Sulfapyridine,-,negative
812,CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,Difloxacin,-,negative
813,CCO[C@H]1O[C@@H]2OC3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,beta_arteether,3A4-Substrate,negative
814,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@@H]3SC(=O)NC3=O)cc1)O2,Troglitazone,UGT-Substrate,positive
815,CNS(=O)(=O)Cc1ccc2[nH]cc(CCCN3CCN(c4ncncc4OC)CC3)c2c1,Avitriptan,2D6-Substrate,negative
816,NCC(=O)CCC(=O)O,Aminolevulinic Acid,Solute_carrier_family_15_member_2-Substrate,negative
817,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,Methaqualone,-,negative
818,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1,Sparteine,2D6-Inhibitor,negative
819,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
820,NC(=O)NN=Cc1ccc([N+](=O)[O-])o1,Nitrofural,2D6-Substrate,negative
821,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,Capecitabine,2C9-Inhibitor,negative
822,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,Moracizine,-,negative
823,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
824,CC(C=CC1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)O,Alitretinoin,1A2-Inhibitor,negative
825,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,Manidipine,2D6-Inhibitor,negative
826,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,-,negative
827,CN(C)CCCN1c2ccccc2CCc2ccccc21,Imipramine,UGT-Substrate,positive
828,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine_R,2C8-Substrate,negative
829,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2E1-Inhibitor,negative
830,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2,aflatoxin_B1,1A2-Substrate,negative
831,CCCN(CCC)CCc1cccc2c1CC(=O)N2,Ropinirole,2D6-Inhibitor,negative
832,CC[Hg]Sc1ccccc1C(=O)[O-],Thiomersal,GST-Inhibitor,negative
833,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
834,O=C(O)CCCCC=C(c1ccccc1)c1cccnc1,Isbogrel,-,negative
835,CC[C@@]1(c2ccccc2)C(=O)NC(=O)N(C)C1=O,Methylphenobarbital,-,negative
836,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
837,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)NC(N)=O,ABT_438,2E1-Substrate,negative
838,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],Trospium chloride,-,negative
839,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
840,Clc1ccc(CO[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Miconazole,19A-Inhibitor,negative
841,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,Sulfadoxine,-,negative
842,Cc1cn[nH]c1,Fomepizole,2E1-Inhibitor,negative
843,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,Zidovudine,UGT-Substrate,positive
844,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
845,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1,Cefradine,Solute_carrier_family_15_member_1-Inhibitor,negative
846,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,Ambroxol,-,negative
847,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Chloroquine,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
848,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Duloxetine,2D6-Substrate,negative
849,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Adenosine,Sodiumbile_acid_cotransporter-Inducer,negative
850,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,licofelone,2D6-Substrate,negative
851,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,Tolbutamide,CP2CI-Substrate,negative
852,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,Melatonin,19A-Inhibitor,negative
853,CC(N)C(=O)c1ccccc1,Cathinone,-,negative
854,CCC(=C(CC)c1ccc(O)cc1)c1ccc(O)cc1,Diethylstilbestrol,19A-Inducer,negative
855,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
856,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,Desvenlafaxine,2D6-Substrate,negative
857,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,Furosemide,2E1-Substrate,negative
858,Oc1ncnc2[nH]ncc12,Allopurinol,2E1-Inhibitor,negative
859,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
860,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,Rifabutin,-,negative
861,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
862,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
863,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,genistein,1A2-Substrate,negative
864,Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfatroxazole,-,negative
865,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,Voriconazole,-,negative
866,Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,Tocopherol (vit E),2E1-Inhibitor,negative
867,CC(=O)Nc1ccc(OC(C)C)cc1,O_isopropyl_acetaminophen,1A2-Substrate,negative
868,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,Oxymetazoline,UGT-Substrate,positive
869,CCOC(=O)C[C@H](SP(=S)(OC)OC)C(=O)OCC,Malathion,-,negative
870,COc1ccc([N+](=O)[O-])cc1,4_nitroanisole,2E1-Substrate,negative
871,CN[C@]1(c2ccccc2Cl)CCCCC1=O,Esketamine,2B6-Substrate,negative
872,CCCSP(=S)(OCC)Oc1ccc(SC)cc1,sulprofos,2D6-Substrate,negative
873,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,Rivastigmine,2D6-Inhibitor,negative
874,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,Clozapine,2E1-Inhibitor,negative
875,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
876,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
877,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,negative
878,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
879,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
880,Cc1cccc(C)c1NC(=O)[C@H](C)N,Tocainide,-,negative
881,C[C@@H](CN1c2ccccc2Sc2ccc(S(=O)(=O)N(C)C)cc21)N(C)C,Dimetotiazine,3A4-Inhibitor,negative
882,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,Loratadine,2D6-Inhibitor,negative
883,CCC1NC(=O)C(NC(=O)c2ncccc2O)C(C)OC(=O)C(c2ccccc2)NC(=O)C2CC(=O)C(CSC3CN4CCC3CC4)CN2C(=O)C(Cc2ccc(N(C)C)cc2)N(C)C(=O)C2CCCN2C1=O,Quinupristin,-,negative
884,COc1cc2c(CCN3CCN(c4cccc(Cl)c4C)CC3)nn(Cc3c[nH]cn3)c2cc1OC,DY_9760e,2D6-Substrate,negative
885,CC(NCCCOc1cccc2ccccc12)C(F)(F)F,deshydroxy_trifluoro_propranolol,2D6-Substrate,negative
886,S=P(N1CC1)(N1CC1)N1CC1,Thiotepa,GST-Substrate,negative
887,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,temazepam,2C19-Substrate,negative
888,Cl,Hydrochloric Acid,2D6-Inhibitor,negative
889,CN(C)CCCN1c2ccccc2Sc2ccccc21,promazine,2E1-Substrate,negative
890,CC(C)CCC[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3C[C@H](O)[C@]12C,5beta_cholestane_3alpha_7alpha_12alpha_triol,2C19-Substrate,negative
891,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2,Brotizolam,-,negative
892,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,Niclosamide,-,negative
893,CN(C)CCC[C@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Citalopram,2E1-Substrate,negative
894,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
895,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,budesonide,3A4-Substrate,negative
896,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,Pregnenolone,2D6-Substrate,negative
897,Clc1cccc(Cl)c1NC1=NCCN1,Clonidine,19A-Inducer,negative
898,CC(=O)c1cc2cccc(OC[C@H](O)CNC(C)C)c2o1,Befunolol,2D6-Substrate,negative
899,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,Hydrochlorothiazide,Solute_carrier_family_12_member_1-Inducer,negative
900,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
901,NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,Modafinil,-,negative
902,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
903,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,Lofepramine,2D6-Substrate,negative
904,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Vorinostat,UGT-Substrate,positive
905,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
906,C#CCN(C)[C@H](C)Cc1ccccc1,Selegiline,2E1-Inhibitor,negative
907,N=C(N)NC(=N)NCCc1ccccc1,Phenformin,2D6-Substrate,negative
908,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,barnidipine,2D6-Substrate,negative
909,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,Brompheniramine,2E1-Substrate,negative
910,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,Didanosine,Solute_carrier_family_15_member_1-Substrate,negative
911,Cc1ccc(S(=O)(=O)NC(=O)NN2C[C@H]3CCC[C@H]3C2)cc1,Gliclazide,-,negative
912,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
913,CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,diazinion,2E1-Substrate,negative
914,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
915,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,Dextromethorphan,2E1-Substrate,negative
916,CC12CCC3C(CCC4=CC(=O)C=CC43C)C1CCC(=O)O2,Testolactone,-,negative
917,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
918,OCCCOc1cccc(CN2CCCCC2)c1,roxatidine_m5,2D6-Substrate,negative
919,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
920,CCCCC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Propiverine,3A4-Inhibitor,negative
921,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Cilnidipine,-,negative
922,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
923,O=[S@](Cc1cc(OCC2CC2)ccn1)c1nc2ccc(F)cc2[nH]1,H_259_31_R,2C19-Substrate,negative
924,C1CNCCN1,Piperazine,2D6-Substrate,negative
925,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,negative
926,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,Fenofibrate,-,negative
927,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
928,N#Cc1ccc(C2CCCc3cncn32)cc1,Fadrozole,-,negative
929,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Codeine,UGT-Substrate,positive
930,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,Methylprednisolone,-,negative
931,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,Flunitrazepam,-,negative
932,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2CC1CCCCC1,BRN_4201400,1A2-Substrate,negative
933,O=S(=O)([O-])[S-],Thiosulfate,2E1-Inhibitor,negative
934,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,Nefiracetam,-,negative
935,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
936,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,Valsartan,-,negative
937,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,Pentoxyverine,2D6-Substrate,negative
938,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,kaempferol,1A2-Substrate,negative
939,CC(C)(C)C1CCC(C2=C(O)c3ccccc3C(=O)C2=O)CC1,58C80_tautomer_1,2C9-Substrate,negative
940,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,4A11-Inducer,negative
941,NCC1(CC(=O)O)CCCCC1,Gabapentin,GST-Inducer,negative
942,CCCO,Propanol,-,negative
943,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(=O)O,Unoproston,Solute_carrier_organic_anion_transporter_family_member_1A2-Substrate,negative
944,NN=O,Nitrosamine,-,negative
945,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Lercanidipine,P450_HFLA-Substrate,negative
946,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,Colchicine,2E1-Inducer,negative
947,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,Metoclopramide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
948,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,Barnidipine,2D6-Inhibitor,negative
949,O=C(c1cccs1)c1ccc(OCc2nnn[nH]2)c(Cl)c1Cl,tienilic_acid_newderiv_9,2C9-Substrate,negative
950,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
951,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,2C19-Substrate,negative
952,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
953,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
954,CCOP(=S)(OCC)SCSCC,phorate,2C19-Substrate,negative
955,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
956,CC(C)[C@H](N)C(=O)OC[C@H](CO)OCn1cnc2c(=O)nc(N)[nH]c21,Valganciclovir,Solute_carrier_family_15_member_2-Inhibitor,negative
957,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,Eslicarbazepine,UGT-Substrate,positive
958,CC(C)(C)NCC(O)COc1ccccc1C#N,Bunitrolol,2D6-Substrate,negative
959,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@@H]13,Eplerenone,P450_HFLA-Substrate,negative
960,c1ccc(C2(c3ccccc3)C[C@H]2C2=NCCN2)cc1,Cibenzoline,2D6-Substrate,negative
961,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,Ibutilide,-,negative
962,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,Oxycodone,19A-Inhibitor,negative
963,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor,negative
964,CCOP(=S)(OCC)SCCSCC,disulfoton,2D6-Substrate,negative
965,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Dicycloverine,Methyltransferase-Inhibitor,negative
966,Clc1ccc(CON=C(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,Oxiconazole,-,negative
967,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,Deferoxamine,1A1-Inhibitor,negative
968,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digoxin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
969,CCOC(=O)n1ccn(C)c1=S,Carbimazole,-,negative
970,Nc1nc2ccc(OC(F)(F)F)cc2s1,Riluzole,UGT-Substrate,positive
971,CC[C@H](Cc1ccc2c(c1)OCO2)NC,MBDB,2D6-Substrate,negative
972,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,Chlorpromazine,2E1-Inhibitor,negative
973,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,Mepyramine,2D6-Inhibitor,negative
974,c1ccc2[nH]ccc2c1,indole,2E1-Substrate,negative
975,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,Ursodeoxycholic Acid,2E1-Inducer,negative
976,C[C@@H](O)[C@@H]1NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Octreotide,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
977,CCC(C)(C)NCC(O)COc1ccccc1C(=O)CCc1ccccc1,Diprafenone,2D6-Substrate,negative
978,CC(C)[C@]12CC(=O)[C@H](C)[C@H]1C2,alpha_thujone,3A4-Substrate,negative
979,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,mianserin_R,2D6-Substrate,negative
980,C=CCc1cc(OC)c2c(c1)OCO2,myristicin,1A2-Substrate,negative
981,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O,Prasterone,19A-Substrate,negative
982,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,2E1-Inhibitor,negative
983,COc1ccc(OC(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,cp_122_721,2D6-Substrate,negative
984,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@H]5O)O[C@H](CO)[C@H]4O)O[C@H](CO)[C@H]3O)O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Lentinan,GST-Inhibitor,negative
985,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@]21CCC(=O)O1,Canrenone,UGT-Inhibitor,negative
986,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,Glucose,2E1-Inhibitor,negative
987,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Chenodeoxycholic Acid,UGT-Substrate,positive
988,CCC1CC2CC3c4[nH]c5ccc(OC)cc5c4CCN(C2)C13,12_methoxy_ibogamine,2D6-Substrate,negative
989,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
990,CC1(C)O[C@H]2CO[C@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@H]2O1,Topiramate,-,negative
991,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,Probenecid,UGT-Substrate,positive
992,FC(F)OC(F)(F)C(F)Cl,enflurane,2E1-Substrate,negative
993,COc1ccc2c(c1)[nH]c1c(C)nccc12,harmine,2D6-Substrate,negative
994,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Methylergometrine,-,negative
995,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
996,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1,Perospirone,2D6-Substrate,negative
997,C[C@H]1[C@@H]2CC[C@H](C)[C@H]3CC[C@]4(C)OO[C@]23[C@@H](O[C@@H]1OC(=O)CCC(=O)O)O4,Artesunate,-,negative
998,COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,curcumin,2D6-Substrate,negative
999,OCc1cccnc1,Nicotinyl Alcohol (pyridylcarbinol),Coumarin_7_hydroxylase-Substrate,negative
1000,CC=CCC(C)C(=O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Valspodar,-,negative
1001,Cc1cc(=O)n(-c2ccccc2)n1C,Phenazone,CP2CI-Substrate,negative
1002,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,Betaxolol,2D6-Substrate,negative
1003,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,Tienilic Acid,GST-Inhibitor,negative
1004,COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,3_methylether_estradiol,2C19-Substrate,negative
1005,Cc1cccc(C)c1OC[C@H](C)N,Mexiletine,2E1-Substrate,negative
1006,CC(N)Cc1ccccc1,amphetamine,2D6-Substrate,negative
1007,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O,Galactose,SUL-Substrate,negative
1008,C[N+](C)(C)C[C@H](O)CC(=O)[O-],Levocarnitine,2E1-Substrate,negative
1009,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,Rofecoxib,GST-Inducer,negative
1010,COC(F)(F)C(Cl)Cl,Methoxyflurane,2E1-Substrate,negative
1011,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21,Pipemidic acid,-,negative
1012,Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,Clofenotane,19A-Inhibitor,negative
1013,CC(C)N=C(N)N=C(N)Nc1ccc(Cl)c(Cl)c1,Chlorproguanil,-,negative
1014,CC(Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,Tenofovir,-,negative
1015,CC[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Phenprocoumon,-,negative
1016,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,Risperidone,P450_HFLA-Substrate,negative
1017,CN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,Homochlorcyclizine,-,negative
1018,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,Androstanolone,UGT-Substrate,positive
1019,Nc1cc(N2CCCCC2)nc(N)[n+]1[O-],Minoxidil,SUL-Substrate,negative
1020,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
1021,CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,Aprindine,2D6-Substrate,negative
1022,COc1ccc(OC)c([C@H](O)CNC(=O)CN)c1,Midodrine,2D6-Inhibitor,negative
1023,Cc1cc2c3ccccc3ccc2c2ccccc12,6_methylchrysene,2E1-Substrate,negative
1024,O=[P@]1(N(CCCl)CCCl)OCCCN1CCCl,trofosfamide,3A4-Substrate,negative
1025,CCCN[C@@H]1CCc2nc(N)sc2C1,Pramipexole,-,negative
1026,Cc1c(F)c(N2CCN[C@@H](C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,Grepafloxacin,-,negative
1027,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
1028,CCOc1ccc2nc3ccc(=O)cc-3oc2c1,7_ethoxy_resorufin,1A2-Substrate,negative
1029,Nc1ccc(O)c(C(=O)O)c1,Mesalazine,Methyltransferase-Inhibitor,negative
1030,c1ccc(COc2ccc3cccnc3c2)cc1,7_benzyloxy_quinoline,1A2-Substrate,negative
1031,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
1032,Cn1cc[nH]c1=S,Thiamazole,2E1-Inhibitor,negative
1033,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
1034,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
1035,CNCCCN1c2ccccc2CCc2ccc(Cl)cc21,N_desmethyl_clomipramine,2D6-Substrate,negative
1036,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Substrate,negative
1037,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,Levonorgestrel,19A-Inhibitor,negative
1038,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Adriamycin,GST-Substrate,negative
1039,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,Enoxolone,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor,negative
1040,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,Fluticasone,-,negative
1041,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,Streptozocin,2E1-Inducer,negative
1042,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Mometasone,2C8-Inhibitor,negative
1043,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,Mosapride,-,negative
1044,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
1045,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,Levodopa,Methyltransferase-Substrate,negative
1046,Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,Oxatomide,2D6-Inhibitor,negative
1047,Cc1ccc(C(C)C)cc2c(C)ccc1-2,Guajazulen,1A2-Substrate,negative
1048,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,Midazolam,P450_HFLA-Inhibitor,negative
1049,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
1050,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
1051,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
1052,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,indiplon,1A2-Substrate,negative
1053,O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,Atovaquone,-,negative
1054,Oc1c(I)cc(Cl)c2cccnc12,Clioquinol,SUL-Inhibitor,negative
1055,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,Methylphenidate,-,negative
1056,O=[P@]1(NCCCl)OCCCN1CCCl,Ifosfamide,CP2CI-Substrate,negative
1057,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,negative
1058,C=CCC1([C@H](C)CCC)C(=O)NC(=O)NC1=O,Secobarbital,-,negative
1059,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,Zomepirac,3A4-Substrate,negative
1060,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
1061,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
1062,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,deoxycholic_acid,3A4-Substrate,negative
1063,CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Decamethrin,1A2-Substrate,negative
1064,O[C@@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,Nebivolol,2D6-Substrate,negative
1065,CC=O,acetaldehyde,2E1-Substrate,negative
1066,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3OC5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,etoposide,2E1-Substrate,negative
